176 related articles for article (PubMed ID: 38580613)
21. Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.
Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Tseng MH; Kuo YY; Yu SC; Liu MC; Yuan CT; Yang YT; Chuang MK; Ko BS; Tang JL; Sun HI; Chuang YK; Tien HF; Hou HA; Chou WC
Blood Cancer J; 2024 Apr; 14(1):57. PubMed ID: 38594285
[TBL] [Abstract][Full Text] [Related]
22. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.
Bacher U; Haferlach C; Alpermann T; Kern W; Schnittger S; Haferlach T
Haematologica; 2011 Sep; 96(9):1284-92. PubMed ID: 21606170
[TBL] [Abstract][Full Text] [Related]
23. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms.
Vardiman JW
Chem Biol Interact; 2010 Mar; 184(1-2):16-20. PubMed ID: 19857474
[TBL] [Abstract][Full Text] [Related]
24. AML classification in the year 2023: How to avoid a Babylonian confusion of languages.
Huber S; Baer C; Hutter S; Dicker F; Meggendorfer M; Pohlkamp C; Kern W; Haferlach T; Haferlach C; Hoermann G
Leukemia; 2023 Jul; 37(7):1413-1420. PubMed ID: 37120689
[TBL] [Abstract][Full Text] [Related]
25. Clinico-genetic and prognostic analyses of 716 patients with primary myelodysplastic syndrome and myelodysplastic syndrome/acute myeloid leukemia based on the 2022 International Consensus Classification.
Lee WH; Lin CC; Tsai CH; Tien FM; Lo MY; Ni SC; Yao M; Tseng MH; Kuo YY; Liu MC; Tang JL; Sun HI; Chuang YK; Chou WC; Hou HA; Tien HF
Am J Hematol; 2023 Mar; 98(3):398-407. PubMed ID: 36588411
[TBL] [Abstract][Full Text] [Related]
26. Blast counts are lower in the aspirate as compared to trephine biopsy in acute myeloid leukemia and myelodysplastic syndrome expressing CD56.
Drexler B; Tzankov A; Martinez M; Baerlocher S; Passweg JR; Dirnhofer S; Tsakiris DA; Dirks J
Int J Lab Hematol; 2021 Oct; 43(5):1078-1084. PubMed ID: 33709561
[TBL] [Abstract][Full Text] [Related]
27. Clonal evolutions during long-term cultures of bone marrow from de novo acute myeloid leukaemia with trilineage myelodysplasia and with myelodysplastic remission marrow.
Tamura S; Kanamaru A; Takemoto Y; Kakishita E; Nagai K
Br J Haematol; 1993 Jun; 84(2):219-26. PubMed ID: 8398821
[TBL] [Abstract][Full Text] [Related]
28. The implications of revised WHO classification (2008) of chronic myeloid neoplasms.
Găman M; Vlădăreanu AM; Radesi S
Rom J Intern Med; 2011; 49(1):25-30. PubMed ID: 22026249
[TBL] [Abstract][Full Text] [Related]
29. Advances towards genome-based acute myeloid leukemia classification: A comparative analysis of WHO-HAEM4R, WHO-HAEM5, and International Consensus Classification.
Chen X; Yuan L; Zhang Y; Wang F; Ma X; Fang J; Cao P; Liu Y; Liu Z; Liu M; Chen J; Zhou X; Liu M; Jin D; Wang T; Lu P; Liu H
Am J Hematol; 2024 May; 99(5):824-835. PubMed ID: 38321864
[TBL] [Abstract][Full Text] [Related]
30. World Health Organization classification of myelodysplastic syndromes.
Czader M; Orazi A
Curr Pharm Des; 2012; 18(22):3149-62. PubMed ID: 22571693
[TBL] [Abstract][Full Text] [Related]
31. The role of flow cytometry in the classification of myeloid disorders.
Saft L
Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):164-175. PubMed ID: 37991530
[TBL] [Abstract][Full Text] [Related]
32. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
[TBL] [Abstract][Full Text] [Related]
33. The fifth edition of the World Health Organization Classification and the International Consensus Classification of myeloid neoplasms: evolving guidelines in the molecular era with practical implications.
Zheng G; Li P; Zhang X; Pan Z
Curr Opin Hematol; 2023 Mar; 30(2):53-63. PubMed ID: 36728868
[TBL] [Abstract][Full Text] [Related]
34. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
Pleyer L; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl-Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Geissler D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
J Hematol Oncol; 2016 Apr; 9():39. PubMed ID: 27084507
[TBL] [Abstract][Full Text] [Related]
35. A real-world analysis of clinical outcomes in AML with myelodysplasia-related changes: a comparison of ICC and WHO-HAEM5 criteria.
Zhou Q; Zhao D; Zarif M; Davidson MB; Minden MD; Tierens A; Yeung YWT; Wei C; Chang H
Blood Adv; 2024 Apr; 8(7):1760-1771. PubMed ID: 38286462
[TBL] [Abstract][Full Text] [Related]
36. ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia-related changes and normal karyotype.
Prats-Martín C; Burillo-Sanz S; Morales-Camacho RM; Pérez-López O; Suito M; Vargas MT; Caballero-Velázquez T; Carrillo-Cruz E; González J; Bernal R; Pérez-Simón JA
Cancer Med; 2020 Jun; 9(11):3637-3646. PubMed ID: 32216059
[TBL] [Abstract][Full Text] [Related]
37. Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2023 Aug; 98(8):1307-1325. PubMed ID: 37288607
[TBL] [Abstract][Full Text] [Related]
38. A comparative review of classification systems in myelodysplastic syndromes (MDS).
Bennett JM
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011
[TBL] [Abstract][Full Text] [Related]
39. Identification and quantitation of blasts in myeloid malignancies with marrow fibrosis or marrow hypoplasia and CD34 negativity.
Nedumannil R; Sim S; Westerman D; Juneja S
Pathology; 2021 Oct; 53(6):795-798. PubMed ID: 33612271
[No Abstract] [Full Text] [Related]
40. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
